Synairgen plc: Synairgen to Present 60 and 90-day Long COVID Data From Phase 3 SPRINTER Study in Hospitalised COVID-19 Patients at IDWeek 2022

Analysis of 60 and 90-day data from Phase 3 SPRINTER trial in hospitalised COVID-19 patients showed that SNG001 reduced risk of recognised Long COVID symptoms Company to present full analysis

Related Keywords

Washington ,United States ,Namrata Taak ,Geoff Nash ,Mary Conway ,Richard Marsden ,Donna Davies ,Duncan Monteith ,Brooke Clarke ,James Black ,Mary Jane Elliott ,Ratko Djukanovic ,Freddie Barnfield ,Chris Brightling ,Lucy Featherstone ,Numis Securities Limited Joint Broker ,Head Of Communications ,University Of Leicester ,Drug Administration ,Consilium Strategic Communications Financial Media ,Patient Health ,Department Of Respiratory Sciences ,Mkc Strategies Llc Us Media Relations ,University Of Southampton Professors Sir Stephen Holgate ,Respiratory Sciences ,United Kingdom Based ,Fast Track ,Southampton Professors Sir Stephen Holgate ,General Anxiety Disorder ,Functional Assessment ,Chronic Illness Therapy ,Fatigue Scale ,Brief Pain Inventory ,Short Form ,Joint Broker ,Charlie Beeson ,Corporate Finance ,Sunil De Silva ,Securities Limited ,Strategic Communications ,Financial Media ,Investor Relations ,Jane Elliott ,Synairgen ,Present ,Song ,Covid ,Data ,Rom ,Hase ,Printer ,Study ,Hospitalised ,Patients ,Midweek ,022 ,